S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
S&P 500   4,970.63 (-0.81%)
DOW   37,864.79 (+0.24%)
QQQ   415.91 (-1.77%)
AAPL   164.27 (-1.66%)
MSFT   398.62 (-1.40%)
META   480.39 (-4.27%)
GOOGL   152.67 (-2.14%)
AMZN   174.37 (-2.71%)
TSLA   148.39 (-1.03%)
NVDA   807.91 (-4.58%)
AMD   148.64 (-4.15%)
NIO   3.80 (-5.00%)
BABA   68.47 (-0.60%)
T   16.31 (-0.12%)
F   12.05 (-0.08%)
MU   106.85 (-4.54%)
GE   147.29 (-3.69%)
CGC   7.93 (+1.28%)
DIS   111.61 (-0.73%)
AMC   3.20 (+9.59%)
PFE   25.77 (+1.50%)
PYPL   61.87 (-0.37%)
XOM   119.58 (+0.89%)
Free Trial
NASDAQ:IMGO

Imago BioSciences (IMGO) Stock Price, News & Analysis

→ Special FREE offer on stock hotsheets (From DTI) (Ad)
Free IMGO Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$36.01
▼
$36.01
50-Day Range
$35.78
▼
$36.01
52-Week Range
$11.56
▼
$36.09
Volume
N/A
Average Volume
171,367 shs
Market Capitalization
$1.22 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
IMGO stock logo

About Imago BioSciences Stock (NASDAQ:IMGO)

Imago BioSciences, Inc., a clinical stage biopharmaceutical company, discovers and develops small molecule product candidates that target lysine-specific demethylase 1(LSD1), an enzyme that used in the production of blood cells in the bone marrow. Its lead product candidate is bomedemstat, which is in Phase II clinical trials for the treatment of myeloproliferative neoplasms chronic cancers of the bone marrow, such as myelofibrosis, essential thrombocythemia, and polycythemia vera. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

IMGO Stock News Headlines

April 13, 2024 | msn.com
Imago Theatre aims to find out if time-traveling Neanderthals have answers to climate change
April 2, 2024 | seekingalpha.com
Merck: Better Times Ahead On Approvals And Outlook
April 19, 2024 | The Bull Report (Ad)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
February 23, 2024 | benzinga.com
Clarus Lifesciences III, L.P.'s Net Worth
December 21, 2023 | morningstar.com
Anixa Biosciences Inc ANIX
February 23, 2023 | benzinga.com
Harmony Biosciences shares are trading lower after the company reported Q4 financial results.
January 11, 2023 | markets.businessinsider.com
Merck To Complete Acquisition Of Imago
January 11, 2023 | finance.yahoo.com
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
April 19, 2024 | The Bull Report (Ad)
Healthcare Takes A Big Step Forward With The Help Of AI
The average doctor can diagnose an illness correctly 50-90% of the time. But one innovative company's medical AI gets it right 92%+.
January 4, 2023 | msn.com
Looking Into Imago BioSciences's Recent Short Interest
December 30, 2022 | seekingalpha.com
Merck is best performing large U.S. pharma of 2022
December 20, 2022 | finance.yahoo.com
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
December 13, 2022 | markets.businessinsider.com
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ELVT, IMGO, GRAY, USER
December 12, 2022 | finance.yahoo.com
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Essential Thrombocythemia at ASH 2022
December 12, 2022 | finance.yahoo.com
Imago BioSciences Presents Positive Data from Ongoing Phase 2 Study of Bomedemstat in Advanced Myelofibrosis at ASH 2022
December 12, 2022 | markets.businessinsider.com
Merck Commences Tender Offer To Acquire Imago BioSciences
December 9, 2022 | msn.com
How Is The Market Feeling About Imago BioSciences?
November 30, 2022 | seekingalpha.com
Imago BioSciences: The Bone Marrow Cancer Researcher Reaches Milestone
November 30, 2022 | finance.yahoo.com
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 1 Study of Bomedemstat in Combination with Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
November 29, 2022 | finance.yahoo.com
Horizon Therapeutics Fields Takeover Interest From Pharma Giants
November 29, 2022 | benzinga.com
SHAREHOLDER ALERT: The M&A Class Action Firm Announces the Investigation of Imago BioSciences, Inc. - IMGO
November 28, 2022 | markets.businessinsider.com
Analyst Ratings for Imago BioSciences
November 25, 2022 | finance.yahoo.com
Pharma Stock Roundup: MRK to Buy IMGO, ABBV's Skyrizi Gets EU Nod for New Indication
November 24, 2022 | 247wallst.com
Imago Bio Shares Soar on Agreement to Selll to Merck for $1.35 Billion Cash
November 22, 2022 | markets.businessinsider.com
Expert Ratings for Imago BioSciences
November 22, 2022 | markets.businessinsider.com
What 5 Analyst Ratings Have To Say About Imago BioSciences
November 22, 2022 | finance.yahoo.com
Imago (IMGO) Shares Surge 104% on Buyout Offer From Merck
See More Headlines
Receive IMGO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Imago BioSciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMGO
CUSIP
N/A
CIK
1623715
Web
www.imagobio.com
Phone
415-529-5055
Fax
N/A
Employees
27
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.84)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-42,310,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-31.85%
Return on Assets
-30.07%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
13.15
Quick Ratio
13.16

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$6.40 per share
Price / Book
5.63

Miscellaneous

Outstanding Shares
33,822,000
Free Float
28,783,000
Market Cap
$1.22 billion
Optionable
Not Optionable
Beta
2.82
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

Key Executives

Key Competitors

View All Competitors

IMGO Stock Analysis - Frequently Asked Questions

How were Imago BioSciences' earnings last quarter?

Imago BioSciences, Inc. (NASDAQ:IMGO) announced its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.44) EPS for the quarter, missing analysts' consensus estimates of ($0.34) by $0.10.

When did Imago BioSciences IPO?

Imago BioSciences (IMGO) raised $105 million in an initial public offering (IPO) on Friday, July 16th 2021. The company issued 7,000,000 shares at a price of $14.00-$16.00 per share.

This page (NASDAQ:IMGO) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
The “Perfect Storm” for Gold
Gold Safe Exchange
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
He Is Giving Away Bitcoin
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith